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The World Health Organization currently recommends assessing elimination of onchocerciasis by testing
whether Ov16 antibody prevalence in children aged 0–9 years is below 0.1%. However, the certainty of evidence
for this recommendation is considered to be low. We used the established ONCHOSIM model to investigate the
predictive value of different Ov16-antibody prevalence thresholds in various age groups for elimination of oncho-
cerciasis in a variety of endemic settings and for various mass drug administration scenarios. According to our sim-
ulations, the predictive value of Ov16 antibody prevalence for elimination depends highly on the precontrol
epidemiologic situation, history of mass drug administration, the age group that is sampled, and the chosen Ov16-
antibody prevalence threshold. The Ov16 antibody prevalence in children aged 5–14 years performs best in pre-
dicting elimination. Appropriate threshold values for this age group start at 2.0% for very highly endemic areas; for
lower-endemic areas, even higher threshold values are safe to use. Guidelines can be improved by sampling
school-aged children, which also is operationally more feasible than targeting children under age 10 years. The
use of higher threshold values allows sampling of substantially fewer children. Further improvement can be
achieved by taking a differentiated sampling approach based on precontrol endemicity.
agent-basedmodeling; antibodies; disease elimination; infectious disease transmission; mass drug
administration; onchocerciasis; predictive value of tests
Abbreviations: IgG4, immunoglobulin G4; MDA, mass drug administration; mf, microﬁlaria(e); PPV, positive predictive value.
Onchocerciasis, a parasitic worm infection also known as river
blindness, is targeted for elimination in Africa by 2025 through
annual or semiannual mass drug administration (MDA) with
ivermectin (1, 2). This goal requires careful monitoring and eval-
uation of ongoing transmission and recrudescence of infection.
The traditional parasitological method of counting microﬁlariae
(mf) in skin snips (superﬁcial skin biopsies) is not sensitive en-
ough when prevalence and intensity of infection become very
low after prolonged control (3). Therefore, the World Health
Organization recommends basing the decision to stop MDA on
2 more-sensitive techniques to detect ongoing or returning trans-
mission: pool screening of the vector blackﬂies for presence of
parasite DNA, and serological surveys among children under the
age of 10 years for presence of Ov16 antibodies (4). The current
recommendation is that the prevalence of Ov16 antibodies
should be under 0.1% before considering stoppingMDA, which
requires sampling several thousand children. The certainty of evi-
dence for this recommendation is considered low (4).
An enzyme-linked immunosorbent assay for anti-Ov16
immunoglobulin G4 (IgG4) has been used for monitoring and
evaluation of onchocerciasis control in Latin America (5–12)
and Africa (13–19), and this is the technique currently recom-
mended by the World Health Organization to evaluate anti-
Ov16 IgG4 (4). A standardized point-of-contact test has been
also developed, using lateral ﬂow strips for detection of anti-
Ov16 IgG4, optionally combined within a biplex for simulta-
neous detection of Wb123 antibodies againstWuchereria ban-
crofti (20, 21). Further validation of this point-of-contact test is
still required for it to possibly replace the enzyme-linked immu-
nosorbent assay as the technique recommended by the World
Health Organization (4). Recently, we predicted how serologi-
cal tests in general would perform in African settings, and we
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concluded that test results—regardless of technique—strongly
depend on the precontrol endemicity, meaning that a one-size-
ﬁts-all protocol might lead to stopping MDA too soon in high-
endemic settings and later than necessary in low-endemic ones
(22).
We investigated the predictive value of Ov16 antibody prev-
alence for elimination of onchocerciasis under different diag-
nostic criteria and sampling strategies.We used the established
ONCHOSIM model to simulate a variety of endemic settings
andMDA scenarios and to calculate the probability of elimina-
tion for a range of threshold values of the Ov16 antibody prev-
alence in various age groups. Based on this, we provide more
tailored guidelines for the use of Ov16 antibody prevalence as
an indicator for elimination of African onchocerciasis.
METHODS
To evaluate the predictive value of Ov16 antibody preva-
lence in assessing elimination of African onchocerciasis, we
used ONCHOSIM (23), an individual-based model for trans-
mission and control of onchocerciasis that has been extensively
used to support decision making in onchocerciasis-control pro-
grams in Africa (24–34). In Web Appendix 1 (available at
https://academic.oup.com/aje), we describe how transmis-
sion and control are modeled with ONCHOSIM.
For this study, we assumed that an individual’s Ov16 sero-
status is a binary variable, similar to the IgG4-based Ov16
antibody rapid diagnostic test: Individuals are either seropos-
itive or seronegative; degrees of antibody levels are not con-
sidered. Because it is not exactly known how seroconversion
is triggered and how long it takes after the trigger for an indi-
vidual to become seropositive, we previously considered 3
alternative hypotheses (22). Given that some studies suggest
that antibodies can be detectable before skin mf (35, 36)
(although this concerns total IgG antibodies and not the more
speciﬁc IgG4 used for Ov16 testing), in the present study we
assumed that Ov16 seroconversion occurs when the ﬁrst
male or female worm in the human body has matured. Sero-
conversion can thus precede the occurrence of mf in the skin
if a single worm or single-sex infection triggers seroconver-
sion, but it can also coincide with the appearance of mf when
a male-female worm pair is present. Antibody positivity in
combination with mf negativity might also occur due to
false-negative mf tests at low mf densities or after clearance
of infection. We further assumed 2 extremes concerning ser-
oreversion: seropositivity is either lifelong (i.e., no serorever-
sion) or lasts until the last adult female worm in an individual
has died (i.e., instant seroreversion). Some degree of seropos-
itivity loss was recently demonstrated in a study in Togo, but
the study did not allow for careful quantiﬁcation of this pro-
cess (37). Last, because the risk that misclassiﬁcation of an
individual’s serostatus might vary between different types
of Ov16 antibody tests, we performed a reference analysis
assuming that we knew the exact serostatus of each individ-
ual. InWeb Appendix 2, we explain how the reader can inter-
pret our results accounting for misclassiﬁcation of serostatus.
Using ONCHOSIM, we simulated trends in prevalence of
infection andOv16 antibody prevalence for 750 scenarios related
to precontrol endemicity (5 levels; details provided in Web
Appendix 3) and MDA frequency (annual vs. semiannual),
coverage (60%, 70%, or 80%), and duration (1–25 years). For
each scenario, we evaluated the Ov16 prevalences in various
age groups 1 year after the last MDA round and compared
these with the simulation outcome in terms of ongoing trans-
mission versus elimination (nonzero vs. zero mf prevalence
50 years after the last MDA round). Because ONCHOSIM is
a stochastic simulation model (i.e., predictions vary because
events within the simulation occur in a random fashion), each
scenario was simulated 10,000 times, yielding a sample of
10,000 draws from the joint distribution of Ov16 prevalence
and the simulation outcome in terms of ongoing transmission
versus elimination. See Figure 1A–C for an illustration. For
each of the 750 scenarios and a range of Ov16 antibody preva-
lence thresholds (0%–100% in 0.1% steps), we categorized
the 10,000 repeated Ov16 prevalence outcomes (Table 1) as
true positive (Ov16 antibody prevalence under the threshold
value and simulation resulting in elimination), false negative
(above the threshold value but still resulting in elimination),
false positive (under the threshold value but resulting in ongo-
ing transmission), or true negative (above the threshold and
resulting in ongoing transmission). We used receiver operat-
ing characteristic curves to visualize the sensitivity and speci-
ﬁcity of Ov16 antibody prevalence thresholds for the prediction
of elimination under the range of potential threshold values
(Figure 1D), which we will from here on refer to as threshold
sensitivity and speciﬁcity (as opposed to test sensitivity and
speciﬁcity for detection of antibodies). This whole process was
repeated for Ov16 antibody prevalence in several age groups
within the simulated population, in years: 0–4, 5–9, 10–14, and
15–19, as well as the broader categories of age 0–9 (current tar-
get age group) and 5–14 (school-age children) years. Receiver
operating characteristic curves for different age groups were
compared to identify which age groups provided most informa-
tion about prospects of elimination. We further estimated the
probability of elimination if the Ov16 antibody prevalence is
under the threshold (positive predictive value or PPV) or above
(1 minus the negative predictive value). See Figure 1E for an
illustration. PPV curves were used to assess the predictive value
of threshold values across different endemic settings and MDA
histories.
RESULTS
Ov16 antibody prevalence in school-age children (ages 5–14
years) provides the best information about the probability of
elimination, as illustrated for 4 example scenarios in Figure 2. In
younger children (0–4 years), the Ov16 antibody prevalence is
generally too close to zero to vary informatively with regards to
ongoing transmission. Similarly, the Ov16 antibody prevalence
in older children (15–19 years) saturates towards the plateau
level of 100% (or the maximum detectable level accounting for
imperfect test sensitivity), again resulting in lower variation and
thus relatively less information. The age range of 5–14 years per-
forms best throughout the 750 scenarios considered, especially
when assuming seroreversion after clearance of infection (Web
Figure 1). In general, for scenarios with semiannual MDA, the
total amount of information provided byOv16 serology is lower
than for scenarios with annual MDA (threshold sensitivity and
speciﬁcity are generally lower). This is the result of semiannual
Am J Epidemiol. 2019;188(9):1723–1732
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Figure 1. Overview of analytical steps to evaluate the predictive value of Ov16 antibody prevalence. The ﬁgure considers the procedure for a sin-
gle scenario, which for illustrative purposes we take to represent a setting with precontrol community microﬁlarial load of 55 microﬁlariae (mf) per
skin snip (equivalent to skin mf prevalence of ~80%) and 6 years of annual mass drug administration (MDA). In this example, Ov16 positivity is
assumed to be lifelong; patterns are qualitatively similar when based on the assumption of instant seroreversion. Note that the jagged appearance
of the curves is due to the stochastic nature of the simulations. A) Using ONCHOSIM, we ﬁrst predict trends in the prevalence of skin mf up to 50
years after the last MDA round and classify repeated simulations (graph lines) as resulting in either elimination or ongoing transmission. Here, we
only show 50 of the 10,000 repeated runs performed, of which 8 did not result in elimination. B) From exactly the same repeated simulation runs, we
extracted the predicted prevalence of Ov16 antibodies in selected age groups (example here: children of aged <10 years). C) We then extracted
the frequency distribution of Ov16 antibody prevalence across repeated simulations, 1 year after the last MDA round, and stratiﬁed it by simulation
outcome in terms of elimination (colored areas) and a chosen threshold for Ov16 antibody prevalence (vertical dashed line, here set at 1%). See
Table 1 for the resulting classiﬁcation of simulations and the calculation of sensitivity, speciﬁcity, and positive and negative predictive value of Ov16
antibody prevalence. D) We subsequently plotted threshold sensitivity versus threshold speciﬁcity for the range of threshold values in a receiver
operator characteristic curve. E) Finally, we plotted positive predictive value (PPV, probability of elimination when Ov16 prevalence is under the
threshold) and 1 minus negative predictive value (NPV, probability of elimination when Ov16 antibody prevalence is above the threshold) against
the range of threshold values (horizontal axis). Note that when interpreting this ﬁgure, the threshold value (x-axis) is decided on before observing
the Ov16 antibody prevalence (i.e., the x-axis represents the predeﬁned threshold and not the observedOv16 prevalence).
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Table 1. Example Classiﬁcation of 10,000 Repeated Simulations for Calculation of the Predictive Value of Ov16 Antibody Prevalence for
Elimination of Onchocerciasis
Simulation Outcome 50 Years After Last Round of MDAa
Ov16 Antibody Prevalence 1 Year After
Last Round of MDAb Total
<1% ≥1%
Ongoing transmission 15 (FP) 1,534 (TN) 1,549
Eliminationc 670 (TP) 7,781 (FN) 8,451
Total 685 9,315 10,000
Abbreviations: FN, false negative; FP, false positive; MDA, mass drug administration; mf, microﬁlaria(e); TN, true negative; TP, true positive.
a Simulation scenario shown in Figure 1.
b Example calculation of sensitivity, speciﬁcity, and positive and negative predictive value of a 1% threshold for Ov16 seroprevalence for predic-
tion of elimination: sensitivity = TP/(TP + FN) = 7.9%; speciﬁcity = TN/(TN + FP) = 99.0%; positive predictive value = TP/(TP + FP) = 97.8%;
negative predictive value = TN/(TN + FN) = 16.5%.
c Zero mf prevalence 50 years after the last MDA round, which occurred in (TP + FN)/(TP + FN + TN + FN) = 84.5% of the 10,000 repeated
simulations.
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Figure 2. Receiver operating characteristic curve for Ov16 antibody prevalence as a predictor of onchocerciasis elimination. The panels repre-
sent 4 examples out of 750 scenarios of precontrol community microﬁlarial load (CMFL) and history of mass drug administration (MDA). See Fig-
ure 1 for a description of how the receiver operating characteristic curves were created. Colored lines represent the Ov16 prevalence measured in
different age categories. Symbols represent different threshold values for Ov16 antibody prevalence: 2% (open circle), 5% (open triangle), 10%
(open diamond), 25% (solid square), and 50% (solid circle). Ov16 positivity is assumed to be lifelong, but patterns are qualitatively similar when
based on the assumption of instant seroreversion. See Web Figure 1 for a complete overview of all 750 scenarios considered and both assump-
tions about Ov16 seroreversion. A) Precontrol CMFL of 10 microﬁlariae (mf) per skin snip and 8 rounds of MDA at 60% coverage, resulting in an
overall probability of elimination of 82.6%. B) Same scenario as in A, but with 10 instead of 8 MDA rounds, resulting in an overall probability of elimi-
nation of 98.4%. C) Precontrol CMFL of 55 mf per skin snip and 13 rounds of MDA at 80% coverage, resulting in an overall probability of elimination
of 27.6%. D) Same scenario as in C, but with 15 instead of 13MDA rounds, resulting in an overall probability of elimination of 70.2%.
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MDA resulting in elimination more quickly than annual MDA,
providing less time for Ov16 antibody prevalence levels to
decline than during annual MDA programs. Related to this, the
difference in the amount of information between age groups is
lower in scenarios with semiannualMDA.
In Figure 3, we compare the same 4 example scenarios in
terms of the probability of elimination if the Ov16 antibody
prevalence is under (PPV) or above the threshold (1 minus
the negative predictive value), given different choices of
diagnostic threshold for Ov16 prevalence (horizontal axis) in
children aged either 0–9 or 5–14 years. When sampling chil-
dren aged 0–9 years, the PPV sometimes cannot reach values
close to 100% regardless of the chosen threshold, unless the
a priori probability of elimination (before testing, dashed
line) is already high. For instance, in Figure 3C and 3D, the
maximum PPVs for Ov16 antibody prevalence in children
aged 0–9 years are about 75% and 95%, which are associated
with threshold values very close to 0%. In contrast, the PPV
in children aged 5–14 years can more easily reach 100%, and it
does so for Ov16 antibody prevalence threshold values further
away from 0%. These patterns are largely consistent throughout
the 750 scenarios considered and both hypotheses about the
rate of seroreversion (Web Figure 2).
In Figure 4, we compare the PPV of different example sce-
narios with a reasonable a priori probability of elimination (cho-
sen to be >80%)—that is, situations where we actually might
consider checking progress towards elimination (see Web
Appendix 4 for an overview of the minimum number of MDA
rounds required to achieve 80% probability of elimination). For
instance, under the assumption of lifelong seropositivity, a PPV
of at least 95% can be achieved with an Ov16 threshold of 30%
in settings with precontrol community microﬁlarial load of 10
mf per skin snip, whereas this thresholdmust be 15% in settings
with precontrol community microﬁlarial load of 55 mf per skin
snip. When assuming seroreversion, these threshold values are
13% and 7%, respectively (Figure 4). Threshold values required
to achieve PPVs close to 100% are relatively independent of
history of control (i.e., lines converge within each panel for low
threshold values). Web Figure 3 contains a complete set of
curves for all 750 scenarios (i.e., including those with a priori
probability of elimination of <80%), sampled age groups, and
assumptions about seroreversion. Generally, for settings with
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Figure 3. Probability of elimination of onchocerciasis if the Ov16 antibody prevalence is over or under the threshold. The panels represent 4
examples out of 750 scenarios of precontrol CMFL and history of mass drug administration (same selection as in Figure 2). See Figure 1 for a
description of how the curves were created. The overall probability of elimination (before Ov16 antibody testing) is represented by the horizontal
dotted line in each panel. Here, Ov16 positivity is assumed to be lifelong, but patterns are qualitatively similar when based on the assumption of
instant seroreversion. See Web Figure 2 for a complete overview of all 750 scenarios and age groups considered, as well as both assumptions
about Ov16 seroreversion. A) Precontrol CMFL of 10 microﬁlariae (mf) per skin snip and 8 rounds of MDA at 60% coverage. B) Same scenario as
in A, but with 10 instead of 8 MDA rounds. C) Precontrol CMFL of 55 mf per skin snip and 13 rounds of MDA at 80% coverage. D) Same scenario as
in C, but with 15 instead of 13MDA rounds.
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semiannual MDA, PPVs close to 100% can be achieved with
Ov16 threshold values that are 2–3 percentage points higher
than thresholds appropriate for annualMDA.
In Table 2, we compare the required threshold values for
Ov16 prevalence in children aged 5–14 years to achieve a PPV
of 90%, 95%, or 99% for 5 precontrol infection levels and both
hypotheses regarding seroreversion. The most conservative
threshold for achieving elimination with 99% probability is on
the order of 2.0%, even when accounting for imperfect sensitiv-
ity and speciﬁcity of the diagnostic test (WebAppendix 2).
DISCUSSION
Our study provides evidence that the predictive value of Ov16
seroprevalence for elimination of onchocerciasis depends heavily
on factors that are not or are only partly considered in the current
guidelines: precontrol endemicity, MDA strategy, and age group
tested. To predict elimination with high certainty (high PPV),
threshold values for Ov16 prevalence should be relatively low
for more highly endemic settings, annual MDA programs (vs.
semiannual), and when sampling younger age groups. We have
shown that Ov16 prevalence in school-age children (age 5–14
years) instead of children under age 10 years can provide the best
information on prospects of elimination, that a threshold on the
order of 2.0% for Ov16 seroprevalence in school-age children is
sufﬁciently conservative to ensure high probability of elimination
in the settings where MDA is implemented annually, and that
this threshold is evenmore conservative for settings with semian-
nualMDA.
The 2.0% threshold is markedly higher than the currently
recommended threshold of 0.1%, due to several factors. First,
we considered children of ages 5–14 years, among whom ser-
oprevalences are higher than among children aged 0–9 years,
but they still decline as a result of MDA (22). If we included
only children aged 5–9 years in our sample, which is common
practice in ﬁeld settings, even a hypothetical (and unpractical)
threshold of zero percent would not result in 99% probability
of elimination. Second, our threshold is per village, while the
0.1% is pooled over a larger area where prevalences might
vary from village to village. Our threshold would also need to
be considerably lower if applied to a larger area rather than to a
village. Third, the threshold can be lower if we correct for the
imperfect sensitivity of the Ov16 diagnostic test; for instance, a
threshold of 2% true prevalence would translate to a corrected
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Figure 4. Positive predictive value of Ov16 seroprevalence in children aged 5–14 years for elimination with varying threshold values (horizontal
axis). The 4 panels represent 4 combinations of precontrol community microﬁlarial load (CMFL) and assumptions about reversibility of seropositiv-
ity. Y-axes represent the probability of elimination if the Ov16 antibody prevalence is under the threshold as deﬁned by the x-axis (i.e., the positive
predictive value). Lines within each panel represent different histories of mass drug administration (number of rounds and coverage, with annual
frequency), but only those that were predicted to result in a priori probability of elimination of at least 80% (i.e., before measuring Ov16 antibody
prevalence (dashed line)). Web Figure 3 shows similar plots for all simulated scenarios, sampled age groups, and assumptions about serorever-
sion. A) Precontrol CMFL of 10 microﬁlariae (mf) per skin snip with seropositivity assumed to be lifelong. B) Precontrol CMFL as in A, but seroposi-
tivity is assumed to revert when the last female worms in a host dies. C) Precontrol CMFL of 55 mf per skin snip with seropositivity assumed to be
lifelong. D) Precontrol CMFL as in C, but seropositivity is assumed to revert when the last female worms in a host dies.
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threshold of 1.3% in case of 60% sensitivity and 99.9% speci-
ﬁcity of the diagnostic test (see alsoWebAppendix 2). Last, we
assumed that all children were included in the survey; sampling
variation is higher when only some of the children are included,
meaning that the threshold needs to be lower to achieve the
same predicted probability of elimination. Based on the above,
we advocate further operational research into the value of differ-
ent geographical and within-village sampling schemes, as well
as the potentially higher value of looking at Ov16 prevalence
proﬁles over wider age ranges rather than summary prevalences
over a mix of age groups.
Although the original strategy for Ov16 seroprevalence as an
indicator was based on the (implicit) assumption that children
born during the MDA program have not been exposed to infec-
tion, this assumption is not strictly necessary. With imperfect
population coverage of MDA there will always be a chance of
residual transmission between MDA rounds. We have shown
that even with imperfect coverage of MDA (i.e., 60%–80% in
our simulations) one can settle on a single threshold value that
works for different MDA histories. Further, in settings where
MDA is implemented semiannually, it is very possible that,
after 6–7 years of MDA, elimination is achieved but some
school-age children are seropositive because of seroconversion
before the start of MDA, which is accounted for in our simula-
tions (we explicitly simulate the life histories of individuals).
Therefore, themodel predicts that in settings whereMDA is im-
plemented semiannually, thresholds can be set higher to avoid
unnecessary continuation ofMDA. However, we chose to pres-
ent thresholds as applicable for annualMDAprograms, because
this frequency is most commonly implemented, and note that
these thresholds are conservative for settings with semiannual
MDA. IfMDA is scaled up to a semiannual frequency at a wide
scale, further simulations with our model could inform to what
extent the threshold could be relaxed.
An operational beneﬁt of targeting school-age children is
that this group is easier to sample. Moreover, the relatively
higher threshold value requires fewer samples to prove statis-
tically that the prevalence is under the threshold. A study in
Uganda highlighted the challenges in meeting the sampling
requirements to statistically conﬁrm the 0.1% seropositivity
threshold criterion (15). To achieve an upper 95%-conﬁdence
bound under a 0.1% threshold, one needs to observe 0 posi-
tives among 3,000 independently and identically distributed
samples (see Web Appendix 5 for details) (38). In contrast, a
threshold of 2% would require zero positives among a mere
148 independently and identically distributed samples. In
general, more samples are needed if these are pooled over
multiple geographical locations (e.g., villages), because sam-
ples from different locations cannot safely be assumed to be
independently and identically distributed due to potential dif-
ferences in Ov16 seroprevalence between locations (the sub-
ject of an ongoing modeling study). Still, a higher threshold
prevalence means that fewer samples are needed, and that sta-
tistically sound inferences might even be made for single lo-
cations. Sampling all school-age children in a reasonably
large village might provide enough statistical power for infer-
ence regarding that particular village.
The decision to stop MDA will most likely be made at the
level of implementation units, and therefore pooling results
over villages in some form will be inevitable. We strongly
advise against calculating Ov16 prevalence simply based on
pooled village numerators and denominators, because this
might lead to a highly heterogeneous sample with regard to
precontrol endemicity, one of the most important determinants
of both the prospect of elimination (22, 32) and the predictive
value of Ov16 antibody prevalence (as shown in the present
study). It would be safer to base stopping criteria on individual
village-level prevalences (e.g., a criterion based on the propor-
tion of sampled villages having a prevalence under the thresh-
old value). Pooling Ov16 prevalence over villages that are
randomly selected regardless of transmission conditions (as is
currently recommended) further increases the risk of diluting
Ov16 prevalence levels, requiring a much lower threshold
than strictly necessary. We therefore recommend that decision
protocols include improved geographical sampling strategies
based on trying to select the most highly endemic communi-
ties within a transmission focus, and a differentiated approach
to evaluating survey results based on precontrol endemicity.
Table 2. Simulation-Based Threshold Values for Ov16 Antibodies in Children Aged 5–14 Years That Are Consistent With High Probability of
Elimination
Precontrol CMFLa (mf/ss)
Threshold for Ov16 Antibody Prevalence Targetb
≥90%Probability of Elimination ≥95%Probability of Elimination ≥99%Probability of Elimination
5 24.5–42.9 19.8–37.3 13.9–28.8
10 18.2–35.3 13.5–29.8 7.8–20.5
30 10.6–24.2 7.6–19.1 2.3–12.6
55 9.5–20.0 6.3–15.3 2.6–9.1
80 8.1–17.8 5.3–13.6 1.9–7.5
Abbreviations: CMFL, community microﬁlarial load; mf, microﬁlaria(e); ss, skin snip.
a CMFL is the geometric mean skin microﬁlarial density in adults of age 20 years or older.
b Threshold values are provided for target probability of elimination (positive predictive value) of 90%, 95%, or 99%. These thresholds were deter-
mined for settings where the a priori probability of elimination (before Ov16 testing) is at least 80%. The left value of each reported range is based
on the assumption of instant seroreversion; the right value is based on the assumption of no seroreversion (i.e., lifelong seropositivity when it
occurs). Threshold values are further based on the assumption that we know the exact serostatus of each individual. In Web Appendix 2 we explain
how the reader can interpret our results accounting for misclassiﬁcation of serostatus.
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In fact, this previously was the strategy for evaluating skin mf
prevalence (1). Obviously, in the absence of any reliable pre-
control endemicity information, a somewhat more conserva-
tive threshold value should be selected.
Our results further underline the importance of the representa-
tion of age groups in Ov16 antibody surveys. In our analysis, we
assumed that the simulated survey samples were representative
of the age and sex distribution of the source population.However,
achieving a representative samplemight be challenging in reality,
and overrepresentation of younger subgroups in the larger sample
(e.g., children 5–9 years old, within the proposed target group of
school-age children) might lead to deﬂation of Ov16 seropreva-
lence and possibly stopping MDA too early. An approach to
counter this would be to base decisions on evaluation of Ov16
prevalences in multiple smaller age categories, each associated
with an appropriate threshold, although this might not be practi-
cal. Therefore, age standardization of Ov16 survey results (22) or
even analyzing full age proﬁlesmight bewarranted.
An important limitation of our study is the lack of understand-
ing of the mechanisms underlying Ov16 seropositivity (i.e., the
trigger for Ov16 seroconversion, the longevity of seropositivity,
and a potential dependence of the seroreversion rate on age). Of
all the potential alternative assumptions regarding the trigger for
Ov16 seroconversion (we assumed the ﬁrst mature worm trig-
gers seroconversion), the most relevant is that seroconversion is
triggered exclusively by appearance of mf. If this were the case,
threshold values would have to be zero simply because the
Ov16 prevalence in children would drop much more quickly
than we predict here. Such a low threshold would make it theo-
retically impossible to evaluate achieving elimination—one can-
not statistically prove that a prevalence is 0%. On the other
hand, if seroconversion is actually triggered by an earlier life
stage than we assume here (e.g., incoming third-stage larvae),
thresholds can even be higher, because the Ov16 would drop
less quickly duringMDA than we currently predict. Most likely,
all parasite life stages contribute to some extent to sensitizing the
host immune system, especially life stages that live (primarily)
outside nodules (i.e., third stage, male adult worms, and mf). As
such, we believe that our assumption of the adult worm as the
main trigger represents the whole spectrum best. Longitudinal
ﬁeld studies comparing decline in prevalence of skin mf and
Ov16 antibodies during MDA might help further elucidate the
relative importance of all potential triggers for seroconversion.
To address the issues regarding the longevity of seropositivity,
we applied 2 assumptions that are at the polar opposite extremes
of the longevity scale (Ov16 seropositivity is either 1) lifelong or
2) lost as soon as the last female worm dies) and based our rec-
ommendations on the most conservative one (i.e., resulting in
the lowest threshold values). Most likely, the truth lies some-
where in between and will be dependent on multiple factors,
including age, frequency of exposure, and duration of exposure.
Longitudinal studies would have to be performed to better char-
acterize the potential range of seroreversion responses.
Some uncertainty remains about the efﬁciency of transmis-
sion in populations with very low infection levels. In the model,
this efﬁciency was determined by 2 important assumptions: 1)
the level of density dependence in transmission, which is caused
by themore efﬁcient transmission of larvae by blackﬂies at lower
infection levels; and 2) the pattern in which human and ﬂy
populations mix with each other (we assume homogeneous
mixing within a village). If transmission is more efﬁcient in low-
prevalence situations than we assumed here—for instance, as a
result of highly assortative mixing (i.e., differential mixing of a
subset of humans with a subpopulation of blackﬂies (39))—the
threshold should be lower than predicted here. Because it is not
precisely known to what extent these 2 factors vary geo-
graphically, caution is required and thresholds should be
deﬁned conservatively.
In conclusion, our study demonstrates that interpretation of
seroprevalence as a measure of ongoing transmission is highly
dependent on the age distribution of the sampled population and
transmission conditions. The currently recommended strategy to
evaluate elimination of onchocerciasis by means of Ov16 anti-
body prevalence in children under age 10 years in a random
selection of villages can be substantially improved. Better predic-
tive power of elimination can be achieved by sampling school-
age children (ages 5–14 years), which allows the use of higher
threshold values for Ov16 prevalence, and these thresholds can
be further increased by taking a differentiated sampling approach
based on precontrol endemicity. The operational beneﬁts of these
insights are 2-fold: 1) school-age children are easier to sample
than the recommendedmix of preschool children and school-age
children; and 2) much smaller sample sizes are required to statis-
tically conﬁrm that Ov16 prevalence is under the threshold. A
challenge remains to prove absence of pockets with residual
transmission in a larger area, which requires good geographical
coverage of selected survey sites, with purposeful sampling of
high-risk settings.
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